Literature DB >> 1601999

Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1.

K E Ugen1, J J Goedert, J Boyer, Y Refaeli, I Frank, W V Williams, A Willoughby, S Landesman, H Mendez, A Rubinstein.   

Abstract

The observation that approximately 70% of HIV-infected pregnant women do not transmit infection vertically suggests that antibody therapy may be effective in the prevention of transmission of HIV infection from mother to child. Currently, there is an incomplete understanding of the processes involved in vertical transmission of HIV infection. The elucidation of the serological basis of maternal immunity as it relates to protection from vertical transmission is the goal of this study. We have screened 20 maternal sera from HIV+ individuals of known vertical transmission status for reactivity with 31 peptides spanning the entire envelope glycoprotein of HIV-1. Of interest was reactivity to regions outside of the V3 loop of gp120. The findings have been examined in relationship to transmission status, as well as to in vitro anti-HIV-1 biological activity. Our results indicate that lack of vertical transmission is correlated with high viral neutralization activity, but not with antisyncytial activity nor with binding to the V3 peptides examined in this study. Also, the transmission group bound to fewer gp41 peptides when compared with the nontransmission group, suggesting that immune responses to gp41 may be important in preventing transmission. These findings may provide insights into the design of passive immunotherapies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601999      PMCID: PMC295892          DOI: 10.1172/JCI115798

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. The NYC Perinatal HIV Transmission Collaborative Study.

Authors:  B S Parekh; N Shaffer; C P Pau; E Abrams; P Thomas; H Pollack; M Bamji; A Kaul; G Schochetman; M Rogers
Journal:  AIDS       Date:  1991-10       Impact factor: 4.177

2.  Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures.

Authors:  W V Williams; H R Guy; D H Rubin; F Robey; J N Myers; T Kieber-Emmons; D B Weiner; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus.

Authors:  L K Vujcic; D H Shepp; M Klutch; M A Wells; R M Hendry; A E Wittek; L Krilov; G V Quinnan
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

4.  LAV/HTLV-III in 20-week fetus.

Authors:  E Jovaisas; M A Koch; A Schäfer; M Stauber; D Löwenthal
Journal:  Lancet       Date:  1985-11-16       Impact factor: 79.321

5.  Enzyme immunoassay ELISA and EMIT.

Authors:  E Engvall
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

6.  Maternal transmission of acquired immune deficiency syndrome.

Authors:  M J Cowan; D Hellmann; D Chudwin; D W Wara; R S Chang; A J Ammann
Journal:  Pediatrics       Date:  1984-03       Impact factor: 7.124

7.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis.

Authors:  J N Weber; P R Clapham; R A Weiss; D Parker; C Roberts; J Duncan; I Weller; C Carne; R S Tedder; A J Pinching
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

9.  LAV/HTLV-III neutralizing antibodies in the sera of patients with AIDS, lymphadenopathy syndrome and asymptomatic seropositive individuals.

Authors:  G P Faulkner-Valle; A De Rossi; O Dalla Gassa; L Chieco-Bianchi
Journal:  Tumori       Date:  1986-06-30

10.  Allogeneic carrier-specific enhancement of hapten-specific secondary B-cell responses.

Authors:  S K Pierce; N R Klinman
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  22 in total

Review 1.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 2.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

3.  Enhancement of antigen specific humoral immune responses after delivery of a DNA plasmid based vaccine through a contact-independent helium plasma.

Authors:  Richard J Connolly; Jose I Rey; Vance M Lambert; Garrett Wegerif; Mark J Jaroszeski; Kenneth E Ugen
Journal:  Vaccine       Date:  2010-12-31       Impact factor: 3.641

4.  Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.

Authors:  Sallie R Permar; Youyi Fong; Nathan Vandergrift; Genevieve G Fouda; Peter Gilbert; Robert Parks; Frederick H Jaeger; Justin Pollara; Amanda Martelli; Brooke E Liebl; Krissey Lloyd; Nicole L Yates; R Glenn Overman; Xiaoying Shen; Kaylan Whitaker; Haiyan Chen; Jamie Pritchett; Erika Solomon; Emma Friberg; Dawn J Marshall; John F Whitesides; Thaddeus C Gurley; Tarra Von Holle; David R Martinez; Fangping Cai; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Raul Louzao; Samantha Wilkes; Saheli Datta; Marcella Sarzotti-Kelsoe; Hua-Xin Liao; Guido Ferrari; S Munir Alam; David C Montefiori; Thomas N Denny; M Anthony Moody; Georgia D Tomaras; Feng Gao; Barton F Haynes
Journal:  J Clin Invest       Date:  2015-06-08       Impact factor: 14.808

5.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

Review 7.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

8.  Human cord blood mononuclear cells are preferentially infected by non-syncytium-inducing, macrophage-tropic human immunodeficiency virus type 1 isolates.

Authors:  P P Reinhardt; B Reinhardt; J L Lathey; S A Spector
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

9.  Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

Authors:  A J Conley; J A Kessler; L J Boots; J S Tung; B A Arnold; P M Keller; A R Shaw; E A Emini
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

10.  Granulocyte-macrophage colony-stimulating factor mimicry and receptor interactions.

Authors:  J M Von Feldt; C Monfardini; T Kieber-Emmons; D Voet; D B Weiner; W V Williams
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.